has function has role immunizes against disease immunizes recipient urinary bladder cancer Homo sapiens subunit vaccine therapeutic vaccine function subunit vaccine role vaccine in clinical trial role bladder cancer vaccine CDX-1307 vaccine 1082 NCT: https://clinicaltrials.gov/study/NCT01094496 Gene name: hCG-β NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C77858 cancer vaccine Hayleigh Kahn A cancer vaccine for bladder cancer designed to generate an immune response against a protein called human chorionic gonadotropin-beta (hCG-β). hCG-β is made by several types of cancers, including bladder cancer, and has been shown to be associated with shorter times to development of metastases and reduced survival in bladder cancer. Administering the CDX-1307 vaccine will cause the body's immune system to attack bladder cancer cells in order to kill them or otherwise keep them from spreading or coming back. The human monoclonal antibody (B11) directed against the mannose receptor and linked to the beta-subunit of human chorionic gonadotropin (hCG beta) with potential immunostimulating and antineoplastic activities. The monoclonal antibody moiety of human monoclonal antibody B11-hCG beta fusion protein CDX-1307 binds to mannose receptors on antigen presenting cells (APCs), including human dendritic cells (DCs) and macrophages. APCs present the processed hCG beta antigen on their cell surfaces, which may initiate an antibody-dependent cell-mediated cytotoxicity (ADCC) response against hCG beta-expressing tumor cells. 6277 VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=6277 Jie Zheng therapeutic cancer vaccine